AE, adverse event; AESI, adverse event of special interest; AFP, alpha-fetoprotein; ALBI; ALBI, albumin­bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; BOR, best overall response; BSC, best supportive care; CP, Child-Pugh; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; EoT, end of treatment; GGT, gamma-glutamyltransferase; HCC, hepatocellular carcinoma; HR, hazard ratio; IQR, inter-quartile range; ITT, intent-to-treat; Liver function; MVI, macrovascular invasion; OS, overall survival; PD, progressive disease; PR, partial response; Prognosis; Ram, ramucirumab; SD, stable disease; Safety; Survival; TACE, transarterial chemoembolisation; Tumour response; VEGF, vascular endothelial growth factor; VEGFRs, vascular endothelial growth factor receptors